An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
Philipp D. le Coutre
Research Funding - Novartis
Heinz Gisslinger
No relevant relationships to disclose
Pierre Zachee
No relevant relationships to disclose
Vikas Gupta
Consultant or Advisory Role - Incyte; Novartis; Sanofi ; YM BioSciences
Honoraria - Incyte; Novartis
Other Remuneration - Incyte; Novartis
Jose Ricardo Perez
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nora Schenk
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Suresh Vutukuru
Employment or Leadership Position - Novartis
Carmen Garcia-Hernandez
No relevant relationships to disclose
Renato Tavares
No relevant relationships to disclose
Monica Bocchia
No relevant relationships to disclose
Dietger Niederwieser
Consultant or Advisory Role - Novartis
Honoraria - Novartis